Protein / target
Mucin-1
Protein at a glance
Biological role
Transcription coregulator
Strongest disease association
Gout
Therapeutic position
Clinically advancing target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
The alpha subunit has cell adhesive properties.
View complete UniProt function annotationHide complete annotation
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack
Subcellular location
Domains and Gene Ontology detail (18)Hide
Domains & features
Gene Ontology
- Capical plasma membrane
- Cchromatin
- Cextracellular exosome
- Cextracellular space
- CGolgi lumen
- Cnucleus
- Cplasma membrane
- Cvesicle
- Fp53 binding
- FRNA polymerase II cis-regulatory region sequence-specific DNA binding
- Ftranscription coregulator activity
- PDNA damage response, signal transduction by p53 class mediator
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Transcriptional regulation
- ·RNA polymerase II cis-regulatory region sequence-specific DNA binding
- ·transcription coregulator activity
- ·negative regulation of transcription by competitive promoter binding
- ·positive regulation of transcription by RNA polymerase II
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene MUC1
Gene-level evidence surfaced through the gene MUC1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
12 compounds recorded · 10 in clinical development · 2 earlier-stage
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Strong
Other modalities — Strong
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.
Related family literature
Papers about “Mucins” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.
via Mucins
via Mucins
Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.